Cardiovascular proteomics is a specialized branch of proteomics that focuses on the comprehensive study of proteins involved in cardiovascular health and disease. Proteomics, the large-scale analysis of proteins, plays a crucial role in unraveling the complex molecular mechanisms underlying cardiovascular conditions such as heart disease and stroke. By examining the complete set of proteins present in the cardiovascular system, researchers aim to identify biomarkers for early disease detection, understand the pathways involved in disease progression, and discover potential therapeutic targets. The application of advanced mass spectrometry and other high-throughput technologies enables the systematic analysis of protein expression, post-translational modifications, and interactions within the intricate network of proteins associated with the cardiovascular system. The insights gained from cardiovascular proteomics not only deepen our understanding of the molecular basis of cardiovascular diseases but also pave the way for the development of innovative diagnostic tools and targeted therapies, ultimately contributing to improved patient outcomes in the realm of cardiovascular health.
Title : Frequency of residual risk in cardiovascular secondary prevention in patients treated at the Reina Fabiola University Clinic
Agustin Joison, Cordoba Catholic University, Argentina
Title : Revolutionizing heart health through Personalized & Precision Medicine (PPM): Towards personalized cardiovascular prevention, precision cardiac care & rehabilitation via optimizing Cardiac Hospital Networks
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibody-proteases as unique biomarkers, potential targets and translational tools of the next step generation to be used in personalized and precision cardiology practice
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Investigation of bergapten’s pharmacological activity against doxorubicin induced cardiotoxicity: supporting evidence from cellular and animal models
Bijoy Krishna Banik, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, India